Komori
Semiannual Report4549EIKEN CHEMICAL CO.,LTD.Pharmaceuticals

Semiannual Report — FY2026 H1

What EIKEN CHEMICAL CO.,LTD. reported for the period from 2026-04-01 to 2027-03-31.

How much it says
42Thin
What moved here
7named for the first time
Its own wording
26terms
Which filing this is
37/ 37newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist

During the interim consolidated accounting period, net sales were ¥21,388 million, up 4.7% year on year, while operating income of ¥1,587 million, down 8.2%, and ordinary income of ¥1,616 million, down 6.6%, both declined. Interim net income attributable to owners of the parent was ¥1,125 million, down 62.2%. Cash and cash equivalents stood at ¥11,444 million at the end of the period, and dividends were resolved for payment on 9 June 2026 and scheduled for payment on 1 December 2026.

Komori's summary of this document, not the document's own words.
42Thin
How much this filing saysA weighted roll-up of 10 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 33 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
61
Detailed
Intensity of change
54
Typical
Strategic shift
56
Typical
Capital movement
38
Thin
Disclosure gaps
0
Almost nothing
Concentration risk
0
Almost nothing
Change in risk
69
Detailed
Financial and capital policy
60
Detailed
Product portfolio
0
Almost nothing
Technology position
73
Detailed
Confidence in strategic bets
R&D spend17億円Money spent making new things.
Cash left over46億円Cash from the business, less what went into equipment.
Spent on equipment5億円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.
EIKEN CHEMICAL CO.,LTD. — FY2026 H1 | Komori